Showing 1–14 of 14 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Styliani Karanika, Tianyin Wang, Addis Yilma, Jennie Ruelas Castillo, James T. Gordy, et al.
Abstract Mycobacterium tuberculosis ( Mtb) is one of the leading infectious causes of death worldwide. There is no available licensed therapeutic vaccine that shortens active tuberculosis (TB) disease drug treatment and prevents relapse, despite the World Health Organization’s ca…
Yu-Min Chuang, Noton K. Dutta, Michael L. Pinn, Chien‐Fu Hung, Petros C. Karakousis
Abstract The lengthy and complicated current regimen required to treat drug-susceptible tuberculosis (TB) reflects the ability of Mycobacterium tuberculosis (Mtb) to persist in host tissues. The stringent response pathway, governed by the dual (p)ppGpp synthetase/hydrolase, Rel M…
Marissa Russell
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups. * H56:IC31 (investigational vaccine) * Placebo 900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are planned to be included, recruited from TB clinics…
Li Liu, Jingjing Hu, Hongzhou Lu
…rotection against M. avium in a mouse model.[15] Therefore, vaccines were worthy to be considered in this area. Funding This work was supported by the Shanghai Commission of Science and Technology (No. 20MC1920100). Conflicts of interest None.
Digby F. Warner, Robin Wood
…itical to better define the TB disease state. Advancing new vaccines, to replace Bacille Calmette-Guérin for the prevention of infection or to prevent progression to disease, is essential to make realistic progress towards global TB control, and a comprehensive roadmap outlines h…
Andrew D. Kerkhoff, Jason Zucker, Diane V. Havlir
Several novel antituberculosis agents, including long-acting injectable agents in mouse models, have shown promise in preclinical and early clinical studies. This encouraging news is offset by the failures of a tuberculosis (TB) vaccine to prevent disease recurrence and a 3-month…
Mursalim Mursalim, Syahida Djasang, Muhammad Adil Awal, Sitti Hadijah, Kusnadi Kusnadi
Mycobacterium tuberculosis is a type of bacteria causing infectious desease called tuberculosis. According to the Makassar City Health Office, total tuberculosis (TB) patients in 2019 were 5,412 with 83% cure rate. The number of TB cases had dropped to 3,250 in 2020 with 85% cure…
Nurlilah Ab Rahman
Tuberculosis is a global disease that carries with it high health and socio-economic burdens onto populations. Millions of people come down with the active form of the disease every year but the proportion of the world population that carries the latent form of this disease is be…
A.A. Danhausa, E.E. Daniel, C.J. Shawulu, Adamu Nuhu, L. Philemon
Regardless of many decades of research, the widespread availability of a vaccine and more recently highly visible WHO efforts to promote a unified global control strategy, Tuberculosis remains a leading cause of infectious mortality. In this paper, a Mathematical Model for Tuberc…
Viktor Pushkarenko, Yana‐Karina Zovdun, Olga Pushkarenko
An 8-year-old boy presented with a 6-month progressively enlarging painless nasal lesion, initially misdiagnosed as infiltrative-suppurative trichophytosis and treated with oral griseofulvin and topical sertaconazole without improvement. The patient's father had pulmonary tubercu…
Mustafa Singapurwala, Poonam Gupta, Rohit Mishra, Amar Mandil, Swapnil Jain, et al.
The magnitude of TB disease, including drug resistance, is huge and alarming in India, being the highest-burden country. The steps taken during the initial decades after getting independence in 1947 were slower and not very effective which is reflected in the timeline depicting c…
Shaki Aktar
The prevalence of tuberculosis (TB) is reducing in Bangladesh, but the emergence of drug resistant tuberculosis make the TB control effort more challenging and questionable. The present study aimed to identify the socio-demographic, behavioral and clinical risk factors for develo…
Dereck Tait, MBChB
This is a Phase I, double-blind, randomized, placebo-controlled safety and immunogenicity study in adults who have recently been successfully treated for drug-susceptible pulmonary Tuberculosis (TB). The safety and immunogenicity profile of escalating doses of AERAS-456 in HIV-ne…
Radojka Savic, PharmD, PhD, Kelly Dooley, MD, PhD, Gustavo Velásquez, MD, MPH
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens…